ACE and cancer: Nevertheless, we observed activation of IFNγ and type-I IFN signaling, as well as other immune-response pathways (for example, antigen presentation), in both cancer and myeloid cells of DCP-IL-12/FLT3L-treated tumors compared to vehicle-treated tumors, as shown by unsupervised ranking of the most deregulated biological processes according to Reactome and Hallmark (Fig. 2i,j and Extended Data Fig. 5f,g).